$CLDX News

Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts

Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $48

Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $40

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation - Slideshow

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript

Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss

Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $61

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Canaccord Genuity Maintains Buy on Celldex Therapeutics, Lowers Price Target to $60

CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Celldex Reports Topline Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis; Study Did Not Meet Key Efficacy Objectives

Guggenheim Maintains Buy on Celldex Therapeutics, Raises Price Target to $100

Celldex Announces Planned Transition of Chief Financial Officer

Celldex CFO Sam Martin Plans To Retire In 2027

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $42 Price Target

Reported Sunday, Celldex Presents Phase 1 CDX-622 Data At EAACI 2026 Showing Bispecific Antibody Targeting Soluble SCF And TSLP Achieves Profound Mast Cell Depletion With Favorable Safety Profile

Reported Sunday, Celldex Presents Phase 2 Data Showing Up To 64% Of Barzolvolimab-Treated CSU Patients Remained Angioedema-Free Seven Months After Last Dose At EAACI Annual Meeting